With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

The Canadian Intellectual Property Office (CIPO) has awarded Palisade Bio a patent for its ileocolonic-targeted ...

BioCryst Pharmaceuticals has signed a definitive agreement to buy Astria Therapeutics with a mix of cash and stock ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

Pfizer's Tukysa could become the first update to the maintenance regimen for HER2-positive breast cancer in over a decade if ...

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...

Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...

The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...